Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Texas: - Houston Methodist San Jacinto Hospital — Baytown, Texas
- UT MD Anderson - The Woodlands — Conroe, Texas
- Houston Methodist Cypress Hospital — Cypress, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Texas: - University of Texas Southwestern Medical Center - Simmons Cancer Center — Dallas, Texas
- University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital — Dallas, Texas
- University of Texas Southwestern Medical Center-Zale Lipshy University Hospital — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Texas: - Investigative Site US067 — Dallas, Texas
- Investigative Site US062 — Denison, Texas
- Investigative Site US011 — Houston, Texas
- Investigative Site US080 — San Antonio, Texas
- Investigative Site US063 — San Antonio, Texas
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in Texas: - UT Southwestern Medical Center at Dallas — Dallas, Texas
- Houston Methodist Office of Graduate - Houston Methodist Neal Cancer Center at Texas Medical Center — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in Texas: - Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology - Austin — Austin, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
- Texas Oncology Gulf Coast — Webster, Texas
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Texas: - Texas Oncology- Baylor Charles A. Sammons Cancer Center — Dallas, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07491445
Sites in Texas: - SCRI - Texas Oncology Dallas — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…
Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Sites in Texas: - HOPE Cancer Center of East Texas — Tyler, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07621718
Sites in Texas: - University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in Texas: - Investigative Site — Houston, Texas
Phase 3 Recruiting Academic/Other
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06593431
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Texas: - Ohio State University Telemedicine — Amarillo, Texas
- Ohio State University-Telemedicine — Austin, Texas
- Ohio State University-Telemedicine — Dallas, Texas
- Ohio State University Telemedicine — Fort Stockton, Texas
- Ohio State University-Telemedicine — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Texas: - Texas Oncology - Central/South Texas — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Texas Oncology - Northeast Texas — Flower Mound, Texas
- Oncology Consultants — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Texas: - Baylor College of Medicine — Houston, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology Dallas — Irving, Texas
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Texas: - Lumi Research — Kingwood, Texas
- Laguna Clinical Research Associates — Laredo, Texas
Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Sponsor: Verastem, Inc.
NCT ID: NCT07644559
Sites in Texas: - START Dallas — Fort Worth, Texas
- MD Anderson Cancer Center — Houston, Texas
- START- San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology San Antonio — San Antonio, Texas
- START Texas — San Antonio, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Texas: - University of Texas at Austin — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Next Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Texas: - Next Oncology - Austin — Austin, Texas
- Next Oncology - Houston — Houston, Texas
- Next Oncology - Dallas — Irving, Texas
- START San Antonio (STSA) — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Texas: - University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Dallas — Irving, Texas
Phase 2 Recruiting Industry
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Texas: - Local Institution - 0085 — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …
Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
- Community Clinical Trials — Kingwood, Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
- UT Health San Antonio — San Antonio, Texas